Sanofi’s new subcutaneous formulation of the multiple myeloma drug Sarclisa (isatuximab) could benefit both patients and healthcare workers by cutting the dosing time and improving the efficiency of outpatient chemotherapy units, a Japanese specialist said on August 28. Speaking at…
To read the full story
Related Article
- Sanofi Debuts Sarclisa SC, Cutting Dosing Time
August 28, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
BUSINESS
- Sarclisa SC Can Meet Patient, Healthcare Worker Needs: Specialist
September 1, 2026
- Merck KGaA to Consolidate Japan Life Science Labs at Haneda Hub
September 1, 2026
- FDA Approves Takeda’s PV Drug Mimrylo
September 1, 2026
- Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
- Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
August 31, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





